Dissociation of gemcitabine chemosensitization by CHK1 inhibition from cell cycle checkpoint abrogation and aberrant mitotic entry

References

• Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardiere C, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364:1817-25; PMID:21561347; http://dx.doi.org/10.1056/NEJMoa1011923
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA, Smith LS, Wood TE, Korn RL, Desai N, Trieu V, Iglesias JL, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol 2011; 29:4548-54; PMID:21969517; http://dx.doi.org/10.1200/JCO.2011.36.5742
   PubMed Web of Science ®Google Scholar
• Ma CX, Janetka JW, Piwnica-Worms H. Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics. Trends Mol Med 2010; PMID:21087899
   PubMed Web of Science ®Google Scholar
• Sorensen CS, Syljuasen RG, Falck J, Schroeder T, Ronnstrand L, Khanna KK, Zhou BB, Bartek J, Lukas J. Chk1 regulates the S phase checkpoint by coupling the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A. Cancer Cell 2003; 3:247-58; PMID:12676583; http://dx.doi.org/10.1016/S1535-6108(03)00048-5
   PubMed Web of Science ®Google Scholar
• O'Connell MJ, Raleigh JM, Verkade HM, Nurse P. Chk1 is a wee1 kinase in the G2 DNA damage checkpoint inhibiting cdc2 by Y15 phosphorylation. EMBO J 1997; 16:545-54; PMID:9034337; http://dx.doi.org/10.1093/emboj/16.3.545
   PubMed Web of Science ®Google Scholar
• Karnitz LM, Flatten KS, Wagner JM, Loegering D, Hackbarth JS, Arlander SJ, Vroman BT, Thomas MB, Baek YU, Hopkins KM, et al. Gemcitabine-induced activation of checkpoint signaling pathways that affect tumor cell survival. Mol Pharmacol 2005; 68:1636-44; PMID:16126823
   PubMed Web of Science ®Google Scholar
• Morgan MA, Parsels LA, Parsels JD, Mesiwala AK, Maybaum J, Lawrence TS. Role of checkpoint kinase 1 in preventing premature mitosis in response to gemcitabine. Cancer Res 2005; 65:6835-42; PMID:16061666; http://dx.doi.org/10.1158/0008-5472.CAN-04-2246
   PubMed Web of Science ®Google Scholar
• Ewald B, Sampath D, Plunkett W. H2AX phosphorylation marks gemcitabine-induced stalled replication forks and their collapse upon S-phase checkpoint abrogation. Mol Cancer Ther 2007; 6:1239-48; PMID:17406032; http://dx.doi.org/10.1158/1535-7163.MCT-06-0633
   PubMed Web of Science ®Google Scholar
• Sorensen CS, Hansen LT, Dziegielewski J, Syljuasen RG, Lundin C, Bartek J, Helleday T. The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair. Nat Cell Biol 2005; 7:195-201; PMID:15665856; http://dx.doi.org/10.1038/ncb1212
   PubMed Web of Science ®Google Scholar
• Syljuasen RG, Sorensen CS, Hansen LT, Fugger K, Lundin C, Johansson F, Helleday T, Sehested M, Lukas J, Bartek J. Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage. Mol Cell Biol 2005; 25:3553-62; PMID:15831461; http://dx.doi.org/10.1128/MCB.25.9.3553-3562.2005
   PubMed Web of Science ®Google Scholar
• Thompson R, Eastman A. The cancer therapeutic potential of Chk1 inhibitors: how mechanistic studies impact clinical trial design. Br J Clin Pharmacol 2013; 76:358-69.
   Web of Science ®Google Scholar
• Petermann E, Woodcock M, Helleday T. Chk1 promotes replication fork progression by controlling replication initiation. Proc Natl Acad Sci U S A 2010; 107:16090-5; PMID:20805465; http://dx.doi.org/10.1073/pnas.1005031107
   PubMed Web of Science ®Google Scholar
• Parsels LA, Morgan MA, Tanska DM, Parsels JD, Palmer BD, Booth RJ, Denny WA, Canman CE, Kraker AJ, Lawrence TS, et al. Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells. Mol Cancer Ther 2009; 8:45-54; PMID:19139112; http://dx.doi.org/10.1158/1535-7163.MCT-08-0662
   PubMed Web of Science ®Google Scholar
• Matthews DJ, Yakes FM, Chen J, Tadano M, Bornheim L, Clary DO, Tai A, Wagner JM, Miller N, Kim YD, et al. Pharmacological Abrogation of S-Phase Checkpoint Enhances the Anti-Tumor Activity of Gemcitabine In Vivo. Cell Cycle 2007; 6:104-10; PMID:17245119; http://dx.doi.org/10.4161/cc.6.1.3699
   PubMed Web of Science ®Google Scholar
• Daud AI, Ashworth MT, Strosberg J, Goldman JW, Mendelson D, Springett G, Venook AP, Loechner S, Rosen LS, Shanahan F, et al. Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors. J Clin Oncol 2015; 33:1060-6; PMID:25605849; http://dx.doi.org/10.1200/JCO.2014.57.5027
   PubMed Web of Science ®Google Scholar
• Morgan MA, Lawrence TS. Molecular Pathways: Overcoming Radiation Resistance by Targeting DNA Damage Response Pathways. Clin Cancer Res 2015; 21:2898-904; PMID:26133775; http://dx.doi.org/10.1158/1078-0432.CCR-13-3229
   PubMed Web of Science ®Google Scholar
• Sausville E, Lorusso P, Carducci M, Carter J, Quinn MF, Malburg L, Azad N, Cosgrove D, Knight R, Barker P, et al. Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors. Cancer Chemother Pharmacol 2014; 73:539-49; PMID:24448638; http://dx.doi.org/10.1007/s00280-014-2380-5
   PubMed Web of Science ®Google Scholar
• McNeely S, Beckmann R, Bence Lin AK. CHEK again: revisiting the development of CHK1 inhibitors for cancer therapy. Pharmacol Ther 2014; 142:1-10; PMID:24140082; http://dx.doi.org/10.1016/j.pharmthera.2013.10.005
   PubMed Web of Science ®Google Scholar
• Morgan MA, Parsels LA, Parsels JD, Lawrence TS, Maybaum J. The relationship of premature mitosis to cytotoxicity in response to checkpoint abrogation and antimetabolite treatment. Cell Cycle 2006; 5:1983-8; PMID:16931916; http://dx.doi.org/10.4161/cc.5.17.3184
   PubMed Web of Science ®Google Scholar
• Parsels LA, Qian Y, Tanska DM, Gross M, Zhao L, Hassan MC, Arumugarajah S, Parsels JD, Hylander-Gans L, Simeone DM, et al. Assessment of chk1 phosphorylation as a pharmacodynamic biomarker of chk1 inhibition. Clin Cancer Res 2011; 17:3706-15; PMID:21482692; http://dx.doi.org/10.1158/1078-0432.CCR-10-3082
   PubMed Web of Science ®Google Scholar
• McNeely S, Conti C, Sheikh T, Patel H, Zabludoff S, Pommier Y, Schwartz G, Tse A. Chk1 inhibition after replicative stress activates a double strand break response mediated by ATM and DNA-dependent protein kinase. Cell Cycle 2010; 9:995-1004; PMID:20160494; http://dx.doi.org/10.4161/cc.9.5.10935
   PubMed Web of Science ®Google Scholar
• Rawlinson R, Massey AJ. gammaH2AX and Chk1 phosphorylation as predictive pharmacodynamic biomarkers of Chk1 inhibitor-chemotherapy combination treatments. BMC Cancer 2014; 14:483; PMID:24996846; http://dx.doi.org/10.1186/1471-2407-14-483
   PubMed Web of Science ®Google Scholar
• Yuan J, Adamski R, Chen J. Focus on histone variant H2AX: to be or not to be. FEBS Lett 2010; 584:3717-24; PMID:20493860; http://dx.doi.org/10.1016/j.febslet.2010.05.021
   PubMed Web of Science ®Google Scholar
• Aarts M, Bajrami I, Herrera-Abreu MT, Elliott R, Brough R, Ashworth A, Lord CJ, Turner NC. Functional Genetic Screen Identifies Increased Sensitivity to WEE1 Inhibition in Cells with Defects in Fanconi Anemia and HR Pathways. Mol Cancer Ther 2015; 14:865-76; PMID:25673822; http://dx.doi.org/10.1158/1535-7163.MCT-14-0845
   PubMed Web of Science ®Google Scholar
• Gagou ME, Zuazua-Villar P, Meuth M. Enhanced H2AX phosphorylation, DNA replication fork arrest, and cell death in the absence of Chk1. Mol Biol Cell 2010; 21:739-52; PMID:20053681; http://dx.doi.org/10.1091/mbc.E09-07-0618
   PubMed Web of Science ®Google Scholar
• Huang X, Tran T, Zhang L, Hatcher R, Zhang P. DNA damage-induced mitotic catastrophe is mediated by the Chk1-dependent mitotic exit DNA damage checkpoint. Proc Natl Acad Sci U S A 2005; 102:1065-70; PMID:15650047; http://dx.doi.org/10.1073/pnas.0409130102
   PubMed Web of Science ®Google Scholar
• Morgan MA, Parsels LA, Zhao L, Parsels JD, Davis MA, Hassan MC, Arumugarajah S, Hylander-Gans L, Morosini D, Simeone DM, et al. Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair. Cancer Res 2010; 70:4972-81; PMID:20501833; http://dx.doi.org/10.1158/0008-5472.CAN-09-3573
   PubMed Web of Science ®Google Scholar
• Engelke CG, Parsels LA, Qian Y, Zhang Q, Karnak D, Robertson JR, Tanska DM, Wei D, Davis MA, Parsels JD, et al. Sensitization of pancreatic cancer to chemoradiation by the Chk1 inhibitor MK8776. Clin Cancer Res 2013; 19:4412-21; PMID:23804422; http://dx.doi.org/10.1158/1078-0432.CCR-12-3748
   PubMed Web of Science ®Google Scholar
• Lindqvist A, Rodriguez-Bravo V, Medema RH. The decision to enter mitosis: feedback and redundancy in the mitotic entry network. J Cell Biol 2009; 185:193-202; PMID:19364923; http://dx.doi.org/10.1083/jcb.200812045
   PubMed Web of Science ®Google Scholar
• Scorah J, McGowan CH. Claspin and Chk1 regulate replication fork stability by different mechanisms. Cell Cycle 2009; 8:1036-43; PMID:19270516; http://dx.doi.org/10.4161/cc.8.7.8040
   PubMed Web of Science ®Google Scholar
• Zhou BB, Bartek J. Targeting the checkpoint kinases: chemosensitization versus chemoprotection. Nat Rev Cancer 2004; 4:216-25; PMID:14993903; http://dx.doi.org/10.1038/nrc1296
   PubMed Web of Science ®Google Scholar
• Aarts M, Sharpe R, Garcia-Murillas I, Gevensleben H, Hurd MS, Shumway SD, Toniatti C, Ashworth A, Turner NC. Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1. Cancer Discov 2012; 2:524-39; PMID:22628408; http://dx.doi.org/10.1158/2159-8290.CD-11-0320
   PubMed Web of Science ®Google Scholar
• King C, Diaz H, Barnard D, Barda D, Clawson D, Blosser W, Cox K, Guo S, Marshall M. Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor. Invest New Drugs 2014; 32:213-26; PMID:24114124; http://dx.doi.org/10.1007/s10637-013-0036-7
   PubMed Web of Science ®Google Scholar
• Feijoo C, Hall-Jackson C, Wu R, Jenkins D, Leitch J, Gilbert DM, Smythe C. Activation of mammalian Chk1 during DNA replication arrest: a role for Chk1 in the intra-S phase checkpoint monitoring replication origin firing. J Cell Biol 2001; 154:913-23; PMID:11535615; http://dx.doi.org/10.1083/jcb.200104099
   PubMed Web of Science ®Google Scholar
• Koh SB, Courtin A, Boyce RJ, Boyle RG, Richards FM, Jodrell DI. CHK1 Inhibition Synergizes with Gemcitabine Initially by Destabilizing the DNA Replication Apparatus. Cancer Res 2015; 75:3583-95; PMID:26141863; http://dx.doi.org/10.1158/0008-5472.CAN-14-3347
   PubMed Web of Science ®Google Scholar
• King C, Diaz HB, McNeely S, Barnard D, Dempsey J, Blosser W, Beckmann R, Barda D, Marshall MS. LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent Mechanisms. Mol Cancer Ther 2015; 14:2004-13; PMID:26141948; http://dx.doi.org/10.1158/1535-7163.MCT-14-1037
   PubMed Web of Science ®Google Scholar
• Toledo LI, Altmeyer M, Rask MB, Lukas C, Larsen DH, Povlsen LK, Bekker-Jensen S, Mailand N, Bartek J, Lukas J. ATR prohibits replication catastrophe by preventing global exhaustion of RPA. Cell 2013; 155:1088-103; PMID:24267891; http://dx.doi.org/10.1016/j.cell.2013.10.043
   PubMed Web of Science ®Google Scholar
• Beck H, Nahse-Kumpf V, Larsen MS, O'Hanlon KA, Patzke S, Holmberg C, Mejlvang J, Groth A, Nielsen O, Syljuasen RG, et al. Cyclin-dependent kinase suppression by WEE1 kinase protects the genome through control of replication initiation and nucleotide consumption. Mol Cell Biol 2012; 32:4226-36; PMID:22907750; http://dx.doi.org/10.1128/MCB.00412-12
   PubMed Web of Science ®Google Scholar
• Zabludoff SD, Deng C, Grondine MR, Sheehy AM, Ashwell S, Caleb BL, Green S, Haye HR, Horn CL, Janetka JW, et al. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol Cancer Ther 2008; 7:2955-66; PMID:18790776; http://dx.doi.org/10.1158/1535-7163.MCT-08-0492
   PubMed Web of Science ®Google Scholar
• Karnitz LM, Zou L. Molecular pathways: targeting ATR in cancer therapy. Clin Cancer Res 2015; 21:4780-5; PMID:26362996
   PubMed Web of Science ®Google Scholar
• Glanzer JG, Liu S, Wang L, Mosel A, Peng A, Oakley GG. RPA inhibition increases replication stress and suppresses tumor growth. Cancer Res 2014; 74:5165-72; PMID:25070753; http://dx.doi.org/10.1158/0008-5472.CAN-14-0306
   PubMed Web of Science ®Google Scholar
• Kausar T, Schreiber JS, Karnak D, Parsels LA, Parsels JD, Davis MA, Zhao L, Maybaum J, Lawrence TS, Morgan MA. Sensitization of Pancreatic Cancers to Gemcitabine Chemoradiation by WEE1 Kinase Inhibition Depends on Homologous Recombination Repair. Neoplasia 2015; 17:757-66; PMID:26585231; http://dx.doi.org/10.1016/j.neo.2015.09.006
   PubMed Web of Science ®Google Scholar
• Huang X, Halicka HD, Darzynkiewicz Z. Detection of histone H2AX phosphorylation on Ser-139 as an indicator of DNA damage (DNA double-strand breaks). Curr Protoc Cytom 2004; Chapter 7, Unit 7 27.1-27.7; PMID:18770804
   PubMedGoogle Scholar
• Lawrence TS. Ouabain sensitizes tumor cells but not normal cells to radiation. Int J Radiat Oncol Biol Phys 1988; 15:953-8; PMID:3182336; http://dx.doi.org/10.1016/0360-3016(88)90132-0
   PubMed Web of Science ®Google Scholar
• Morgan MA, Parsels LA, Kollar LE, Normolle DP, Maybaum J, Lawrence TS. The combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancer. Clin Cancer Res 2008; 14:5142-9; PMID:18698032; http://dx.doi.org/10.1158/1078-0432.CCR-07-4072
   PubMed Web of Science ®Google Scholar